ENGLEWOOD, Colo., Jan. 22, 2026 /PRNewswire/ -- Zynex, Inc. (ZYXIQ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today issued the following statement regarding the federal indictments of two former executives. "Zynex, Inc. is aware of the federal indictments of two former executives," said John Bibb, Chief Legal Officer. The individuals named in the indictment are no longer employed by Zynex and pl ...

Core Insights - The market has experienced significant declines in stock values of various companies, driven by market volatility, company-specific developments, and broader economic conditions [1][7] Company-Specific Summaries - Glenmede Women in Leadership US Eq (GWILX) saw its price drop by 48.32% to $8.79, indicating market skepticism about its performance despite its focus on gender diversity [2] - Harding Loevner Emerging Markets Portfolio Advisor Class (HLEMX) and Harding Loevner Institutional Emerging Markets Portfolio (HLMEX) experienced declines of 48.42% and 49.43%, respectively, reflecting the inherent risks of investing in volatile emerging markets [3] - SaverOne 2014 Ltd (SVRE) had a stock price decline of 46.61% to $1.89, with increased trading volume suggesting heightened investor interest or concern [4] - Zynex, Inc. (ZYXI) faced a dramatic decline of 55.33% to $0.29, entering Chapter 11 financial restructuring to stabilize its position amid challenges in the medical device sector [5] Market Trends - The significant price movements of these companies highlight the importance of understanding the factors driving market performance, including volatility, industry-specific challenges, and economic conditions [6][7]

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 250 points, down 0.52% to 48,164.83, NASDAQ down 0.37% to 22,971.25, and S&P 500 down 0.56% to 6,778.08 [1] - European shares were lower, with the eurozone's STOXX 600 slipping 0.64%, Spain's IBEX 35 Index down 0.69%, London's FTSE 100 down 0.92%, Germany's DAX 40 down 0.85%, and France's CAC 40 declining 0.40% [5] - Asian markets closed lower, with Japan's Nikkei falling 1.56%, Hong Kong's Hang Seng down 1.54%, China's Shanghai Composite down 1.11%, and India's BSE Sensex down 0.63% [6] Economic Indicators - U.S. retail sales were flat for October compared to September, down from a revised 0.1% gain in the previous month and below market estimates of 0.1% growth [7] - The U.S. economy added 64,000 jobs in November, compared to a loss of 105,000 in the previous month and above market estimates of a 50,000 increase [9] - The U.S. unemployment rate rose to 4.6% in November from 4.3% in the previous month, marking the highest reading since September 2021 [9] - Average hourly earnings rose by 0.1% month-over-month to $36.86 in November, compared to a 0.4% rise in the previous month [9] - U.S. business inventories increased 0.2% month-over-month in September, in line with market estimates [9] - The S&P Global flash composite PMI declined to 53 in December, the lowest reading in six months, down from 54.2 in November [2][9] Commodity Market - In commodity news, oil traded down 2.9% to $55.17, while gold traded up 0.5% at $4,357.00 [4] Company News - SRx Health Solutions Inc shares surged 92% to $0.59 after announcing an agreement to acquire EMJ Crypto Technologies [8] - Rezolve AI PLC shares rose 34% to $3.12 following preliminary December revenue results [8] - Cementos Pacasmayo SAA shares increased 48% to $10.25 after Holcim signed an agreement to purchase 50.01% of the company's owner [8] - Zynex Inc shares dropped 53% to $0.31 after entering Chapter 11 court-supervised financial restructuring [8] - Lightwave Logic Inc shares fell 19% to $3.05 after announcing the pricing of an 11.67 million share common stock offering [8] - Navan Inc shares decreased 17% to $12.21 after reporting third-quarter results [8]

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 250 points, down 0.52% to 48,164.83, NASDAQ down 0.37% to 22,971.25, and S&P 500 down 0.56% to 6,778.08 [1] - European shares were lower, with the eurozone's STOXX 600 slipping 0.64%, Spain's IBEX 35 Index down 0.69%, London's FTSE 100 down 0.92%, Germany's DAX 40 down 0.85%, and France's CAC 40 declining 0.40% [5] - Asian markets closed lower, with Japan's Nikkei down 1.56%, Hong Kong's Hang Seng down 1.54%, China's Shanghai Composite down 1.11%, and India's BSE Sensex down 0.63% [6] Economic Indicators - U.S. retail sales were flat for October compared to September, down from a revised 0.1% gain in the previous month and below market estimates of 0.1% growth [7] - The U.S. economy added 64,000 jobs in November, compared to a loss of 105,000 in the previous month and above market estimates of a 50,000 increase [9] - The U.S. unemployment rate rose to 4.6% in November from 4.3% in the previous month, marking the highest reading since September 2021 [9] - Average hourly earnings for private nonfarm payrolls rose by 0.1% month-over-month to $36.86 in November, compared to a 0.4% rise in the previous month [9] - U.S. business inventories increased 0.2% month-over-month in September, in line with market estimates [9] - The S&P Global flash composite PMI declined to 53 in December, the lowest reading in six months, down from 54.2 in November [2][9] Commodity Market - Oil traded down 2.9% to $55.17, while gold traded up 0.5% at $4,357.00, silver up 0.1% to $63.59, and copper down 1% to $5.3560 [4] Company News - SRx Health Solutions Inc shares surged 92% to $0.59 after announcing an agreement to acquire EMJ Crypto Technologies [8] - Rezolve AI PLC shares rose 34% to $3.12 following preliminary December revenue results [8] - Cementos Pacasmayo SAA shares increased 48% to $10.25 after Holcim signed an agreement to purchase 50.01% of the company's owner [8] - Zynex Inc shares dropped 53% to $0.31 after entering Chapter 11 court-supervised financial restructuring [8] - Lightwave Logic Inc shares fell 19% to $3.05 after announcing the pricing of an 11.67M share common stock offering [8] - Navan Inc shares decreased 17% to $12.21 after reporting third-quarter results [8]

Core Insights - Heartbeam Inc's shares increased significantly by 43.3% to $0.86 in pre-market trading following the announcement of its regulatory strategy after the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software [1][2] Company Developments - Heartbeam is exploring multiple regulatory options, including an appeal process or a 510(k) resubmission to demonstrate that its device is equivalent to legally marketed products [1] Market Movements - Other notable pre-market stock movements include: - SMX PLC surged 73.1% to $30.12 after a previous jump of 194% [6] - Zenta Group Co Ltd gained 26.7% to $3.18 [6] - Waton Financial Ltd rose 21.1% to $3.74 [6] - Verrica Pharmaceuticals Inc increased by 9.7% to $7.36 after announcing a $50 million private placement [6] - Conversely, several companies experienced declines, such as: - FBS Global Ltd fell 24.3% to $0.51 [6] - Tilray Brands Inc declined 15% to $0.88 following a reverse stock split announcement [6] - Solo Brands Inc dipped 14.4% to $7.19 after reporting disappointing third-quarter results [6]

Company Highlights - Zynex, Inc. (NASDAQ:ZYXI) experienced a 98% increase in stock price, reaching $1.46 from a low of $0.695, with a trading volume exceeding 66 million shares, driven by strong Q3 results [1][6] - Pasithea Therapeutics Corp. (KTTA) saw a 69.4% rise in stock price to $0.826, peaking at $1.34 during the day, with a trading volume of approximately 124 million shares, following a $1 million grant from the ALS Association for ALS research [2][6] - Amber International Holding Ltd (Nasdaq: AMBR) reported a 59.49% jump in stock price to $2.52, with over 85 million shares traded, and announced a $50 million share repurchase program, reflecting strong business momentum [3][6] - SMX (NASDAQ:SMX) saw its stock price climb by 58.21% to $9.35, with over 12 million shares traded, showcasing strong momentum at the 2025 DMCC Precious Metals Conference [4][6] Market Trends - The market is characterized by significant investor interest and stock price volatility across various sectors, including healthcare, biotechnology, real estate, and technology, driven by company-specific developments and broader market trends [5]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Zynex has released its financial results for the third quarter ending September 30, 2025, and is set to discuss projections and forward-looking statements during the earnings conference call [2][4]. Financial Results - The financial results for the third quarter of 2025 were made available on the company's website [2]. Future Projections - The company will provide forward-looking statements regarding future events, which may include product development, regulatory environment, and sales strategies [3][4].

Zynex (NasdaqGS:ZYXI) Q3 2025 Earnings Call November 18, 2025 09:00 AM ET Company ParticipantsStephen Dyson - CEOVikram Bajaj - CFOOperatorGood morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to turn the conference over to Vikram Bajaj, Chief Financial Officer of Zynex. Please go ahead.Vikram BajajThank yo ...

Financial Data and Key Metrics Changes - Net revenue for Q3 2025 was $13.4 million, a significant decline from $50 million in Q3 2024, primarily due to TRICARE payment suspension and a $2.8 million reduction in revenue related to payments received during the suspension period [11][12] - Gross profit in Q3 2025 was $8.1 million, or 60% of revenue, compared to $39.8 million, or 80% of revenue, in Q3 2024 [12] - Net loss for Q3 2025 was $42.9 million, or $1.42 per share, compared to a net income of $2.4 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Device revenue was $7.1 million, while supplies revenue was $6.3 million in Q3 2025, reflecting the overall decline in net revenue [11] - Sales and marketing expenses decreased by 54% to $9.5 million in Q3 2025, primarily due to headcount reduction [12] Market Data and Key Metrics Changes - The decline in revenue was attributed to changes in payers' claim submission and review practices, resulting in denials and payment delays [11] - Workforce reductions in Q1 and Q2 negatively impacted device orders and new patient onboarding, contributing to the overall revenue decline [12] Company Strategy and Development Direction - The company is focused on a three-part strategy: addressing government agency concerns, managing near-term debt obligations, and improving revenue and cash flow performance [5][6] - A new resupply order fulfillment policy was implemented to enhance patient engagement and compliance [6][7] - The company is actively seeking to raise new capital to fund operations and address the maturity of $60 million in convertible senior notes due in May 2026 [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about progress in addressing compliance and integrity issues, although uncertainty remains regarding TRICARE reinstatement and ongoing investigations [6][10] - Early signs of success were noted in improving sales force productivity and order volumes, despite a reduced sales force [9][10] Other Important Information - The company had $13.3 million in cash and cash equivalents as of September 30, 2025, and experienced a negative cash flow of $6.3 million during the quarter [7][14] - A non-cash asset impairment charge of $30.7 million was recorded, primarily related to goodwill and certain fixed assets [14][15] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating that the call concluded without a Q&A segment [17]